Drug Trial Radar · NCT07735637
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
750
Planned (sponsor's estimate)
Start
Sep 24, 2026
Primary completion
Nov 2, 2028
Study completion Nov 17, 2039
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the efficacy of AZD0120 compared with ASCT in terms of progression-free survival (PFS) according to the International Myeloma Working Group (IMWG) criteria 2016, and MRD negative complete response (CR) rate at 9 months as assessed by Blinded Independent Central Review (BICR), in participants with TE NDMM. Study details include: * The study duration is estimated to be up to 13 years from the date the first participant is randomised. * For participants in Arm A (AZD0120), the total duration of participant follow-up will be 15 years (including a Long Term Follow-up study) after the last participant has received the AZD0120 infusion. * The treatment duration will be:- Arm A (AZD0120): lymphodepletion over 3 days, a single-day infusion of AZD0120, followed by a maximum of 2 years lenalidomide monotherapy maintenance treatment. * Arm B (ASCT): conditioning therapy over 24 to 48 hours, ASCT, followed by a maximum of 2 years lenalidomide monotherapy maintenance treatment. Disclosure Statement: This is an open-label, randomised study with 2 treatment arms.
Conditions
- Newly Diagnosed Multiple Myeloma (NDMM)
Interventions
AZD0120Biological
Arm A: AZD0120 - autologous BCMA/CD19 dual-targeting CAR-T cells. Participants will receive lymphodepletion conditioning (cyclophosphamide and fludarabine) followed by AZD0120 CAR-T cell infusion.
CyclophosphamideDrug
Arm A: Cyclophosphamide will be given intravenously as lymphodepletion conditioning.
FludarabineDrug
Arm A: Fludarabine will be given intravenously as lymphodepletion conditioning.
Melphalan (part of ASCT)Drug
Arm B - Autologous stem cell transplant: High-dose melphalan will be given over 1-2 days, followed by autologous stem cell rescue.
LenalidomideDrug
Arm A and Arm B: Lenalidomide maintenance treatment will be started in both Arm A and Arm B after AZD0120 therapy or ASCT, respectively. Lenalidomide maintenance on study will be continued up to 2 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to approximately 13 years.
- Minimal Residual Disease (MRD) negative Complete Response Rate (CRR)Time frame: Up to approximately 13 years.
Locations
114 sites in 18 countries. Site status is shown where the registry gives one.
Research Site
Gilbert, Arizona · Not yet recruiting
Research Site
Goodyear, Arizona · Not yet recruiting
Research Site
Phoenix, Arizona · Not yet recruiting
Research Site
Los Angeles, California · Withdrawn
Research Site
Orange, California · Not yet recruiting
Research Site
San Francisco, California · Not yet recruiting
Research Site
Stanford, California · Not yet recruiting
Research Site
Denver, Colorado · Not yet recruiting
Research Site
Jacksonville, Florida · Not yet recruiting
Research Site
Tampa, Florida · Not yet recruiting
Research Site
Atlanta, Georgia · Not yet recruiting
Research Site
Atlanta, Georgia · Not yet recruiting
Research Site
Newnan, Georgia · Not yet recruiting
Research Site
Chicago, Illinois · Not yet recruiting
Research Site
Zion, Illinois · Not yet recruiting
Research Site
Lexington, Kentucky · Not yet recruiting
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
Detroit, Michigan · Not yet recruiting
Research Site
Rochester, Minnesota · Not yet recruiting
Research Site
St Louis, Missouri · Not yet recruiting
Research Site
Great Neck, New York · Not yet recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
Rochester, New York · Not yet recruiting
Research Site
Stony Brook, New York · Not yet recruiting
Research Site
The Bronx, New York · Not yet recruiting
Research Site
Chapel Hill, North Carolina · Not yet recruiting
Research Site
Charlotte, North Carolina · Not yet recruiting
Research Site
Durham, North Carolina · Not yet recruiting
Research Site
Winston-Salem, North Carolina · Not yet recruiting
Research Site
Cleveland, Ohio · Not yet recruiting
Research Site
Columbus, Ohio · Not yet recruiting
Research Site
Portland, Oregon · Not yet recruiting
Research Site
Philadelphia, Pennsylvania · Not yet recruiting
Research Site
Philadelphia, Pennsylvania · Not yet recruiting
Research Site
Austin, Texas · Not yet recruiting
Research Site
Dallas, Texas · Not yet recruiting
Research Site
Houston, Texas · Not yet recruiting
Showing 40 of 114 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.